Clinical Trial Update: Aliskiren Study of Safety and Efficacy in Senior Hypertensives [Phase 4]

View source ↗

Summary

Novartis has withdrawn a Phase 4 trial evaluating aliskiren for safety and efficacy in senior hypertensive patients. The study has been discontinued.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 4 | Status: WITHDRAWN